RE: Illumina ordered to pay BGI subsidiary $333 million in DNA-sequencing patent case9 May 2022 11:30
I think maybe when the Ranger tech is established a bit more then it might be time to sell the business to a bigger player with more resources to fully make the best of the new technology going forward.
Must admit, haven't been the biggest fan of LR, but cwcd, buying the Canadian outfit, will turn out to be a masterstroke. All now primed and ready to take the US dollars, even the exchange rate is going in favour.
Twix, I think I will soon join you at these levels. A £55M mcap seems bizarre with what's on offer here. It is around a £5M revenue if you work the 10x rule for valuation as was spoken about in the presentation.
I assume that punters haven't quite grasped the significance of the results that came out of the very recent study and research with Laval university. The EDTA tubes along with the Ranger tech blows the Streck industry standard out the water. Brilliant performance which on it's own made them quickly go for some IP, thankfully. Not only disruptive for Illumina, but Streck too . The beauty is it's verified by the university and not some internal offering that would be rubbished by competitors.
Proof of the pudding is labs are convinced enough to completely change their existing set up and move to the Ranger workflow. Now, they don't do that on a whim do they?
Not sure about anyone else but if you've only seen the presentation once then take a little time to look again. You can't take everything in on one viewing. The Ranger tech really can be a massive game changer for Ygen. The results against the Streck tubes is really amazing and unique to Ygen. It really is disruptive for Illumina and Streck. If the IP is watertight then they really do have something very valuable imo. Do yourselves a favour and listen again, it does sound better each time. As for selling now, hmmm!